Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03NHS
|
|||
| Drug Name |
PCO371
|
|||
| Synonyms |
Pco-371; UNII-TE53TU0WSQ; TE53TU0WSQ; PCO-371; 1613373-33-3; SCHEMBL17104864; CHEMBL3976807; US9428505, Compound 7; BDBM64562; PC-0371; J3.591.565F; 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-
Click to Show/Hide
|
|||
| Indication | Hypoparathyroidism [ICD-11: 5A50; ICD-9: 252.1] | Phase 1 | [1] | |
| Company |
Chugai Pharma USA Berkeley Heights, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H32F3N5O6S
|
|||
| Canonical SMILES |
CC1=CC(=CC(=C1CCS(=O)(=O)N2CCC3(CC2)C(=O)NC(=N3)C4=CC=C(C=C4)OC(F)(F)F)C)N5C(=O)NC(=O)C5(C)C
|
|||
| InChI |
1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44(41,42)36-12-10-28(11-13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9-14H2,1-4H3,(H,33,35,39)(H,34,38,40)
|
|||
| InChIKey |
LDZJFVOUPUFOHX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1613373-33-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Parathyroid hormone 1 receptor (PTH1R) | Target Info | Agonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Endocrine and other factor-regulated calcium reabsorption | ||||
| Reactome | Class B/2 (Secretin family receptors) | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Endochondral Ossification | |||
| GPCRs, Class B Secretin-like | ||||
| Osteoblast Signaling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.